Cybin Outlines Upcoming Priorities and Milestones for its Clinical Development ProgramsBusiness Wire • 01/08/23
Cybin Presents CYB003 Preclinical Data at 2022 American College of Neuropsychopharmacology Annual MeetingBusiness Wire • 12/06/22
Cybin Inc. Reports Second Quarter Financial Results and Recent Business HighlightsBusiness Wire • 11/14/22
Cybin to Participate in the Jefferies London Healthcare Conference and Upcoming Investor EventsBusiness Wire • 11/03/22
Cybin Announces Scientific Presentation at the 5th Annual Neuropsychiatric & Psychedelics Drug Development SummitBusiness Wire • 11/01/22
ALTRD.TV's Open Minds Documentary Explores the Promising Future of Psychedelic MedicineBusiness Wire • 10/10/22
Cybin Obtains Exclusive License to a Novel Catalog of Psychedelic-Based CompoundsBusiness Wire • 09/27/22
Cybin Achieves Research and Development Milestones Ahead of Projected TimelinesBusiness Wire • 09/20/22
Cybin Inc. Announces First Participants Dosed in its Phase 1/2a Trial of CYB003 for the Treatment of Major Depressive DisorderBusiness Wire • 08/30/22
Cybin to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceBusiness Wire • 08/25/22
Cybin and Clinilabs Granted Schedule I DEA License for CYB003 Phase 1/2a First-In-Human Clinical TrialBusiness Wire • 08/17/22